Pyridostigmine bromide Mylan 180 mg ilgstošās darbības tabletes Latvja - Latvjan - Zāļu valsts aģentūra

pyridostigmine bromide mylan 180 mg ilgstošās darbības tabletes

mylan ireland limited, ireland - piridostigmīna bromīds - ilgstošās darbības tablete - 180 mg

Reblozyl Unjoni Ewropea - Latvjan - EMA (European Medicines Agency)

reblozyl

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - citi antianēmiskie līdzekļi - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.